| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 13 | 83.4x | 17.6x | Bottom tier | |
Growth | 92 | 23.0% | 7.1% | Top tier | |
Quality | 77 | 3.6% | 4.5% | Top tier | |
Safety | 87 | 0.7x | 2.6x | Top tier | |
Capital Return | 24 | — | 2.15% | Bottom tier | |
Momentum | 68 | 27.9% | 2.3% | Top tier | |
Sentiment | 43 | 6 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced therapies in sports medicine and burn care. Its business is built on MACI for treating knee cartilage defects and a burn care franchise comprising Epicel and NexoBrid; in Q1 FY2026, MACI generated revenue of $56.4 million, while burn care generated $12.0 million, including $10.9 million from Epicel and $1.1 million from NexoBrid.
In Q2 FY2026, revenue reached $77.5 million and gross profit was $56.4 million, equivalent to a gross margin of approximately 72.8%, while net income was $2.2 million and earnings per share were $0.04. This represents an improvement in net income compared with a loss of $6.3 million and negative earnings per share of $0.12 in Q1 FY2026, when revenue was $68.4 million and gross profit was $49.3 million.
Revenue for the trailing twelve-month period in 2026 was approximately $306.3 million, with gross profit of $228.4 million, net income of $24.2 million, and earnings per share of approximately $0.46. By comparison, FY2025 recorded revenue of $276.3 million, gross profit of $205.6 million, and net income of $16.5 million, demonstrating that sales growth is translating into a meaningful improvement in profitability.
Automated analysis for informational purposes only — not investment advice.
The analysts' average price target is $57.5, within a wide range of $46 to $70, with a consensus "Buy" recommendation; the average is approximately 16.6% above the 52-week range high of $49.32. Conversely, no displayed price-to-earnings ratio is available despite trailing twelve-month earnings per share in 2026 of approximately $0.46, while the lowest target of $46 falls within the 52-week range of $28.95–49.32, reflecting meaningful variation in analysts' estimates of the value of growth.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
MACI is the largest driver, generating $56.4 million of total revenue of $68.4 million in Q1 FY2026. The product grew 22% year over year, and its trailing four-quarter growth rate reached 23%. Management raised its FY2026 MACI revenue guidance to a range of $282–288 million following double-digit growth in biopsies and implants.
MACI Arthro aims to expand the use of MACI in smaller femoral condyle defects, particularly those measuring between 2 and 4 square centimeters. Vericel trained more than 1,000 surgeons during FY2025, and trained surgeons were responsible for more than half of MACI implants. Preliminary case data accepted for publication showed reduced postoperative pain, improved range of motion, and faster progression to full weight-bearing, while prospective data collection continues through the MACI clinical outcomes registry.
The contract has a maximum value of $197 million, while the base portion is $35 million and includes approximately $10 million in NexoBrid purchases over 12 months. Management expected to recognize $5–6 million in purchase revenue in the second half of FY2026, beginning in Q3 FY2026, with the remainder recognized in early 2027. Other elements include vendor-managed inventory services and preliminary work for potential use in blast injuries, while additional awards remain optional.
In Q2 FY2026, the company recorded net income of $2.2 million and earnings per share of $0.04, compared with a net loss of $6.3 million and negative earnings per share of $0.12 in Q1 FY2026. Gross margin in Q2 FY2026 was approximately 72.8%, based on gross profit of $56.4 million and revenue of $77.5 million. On a trailing twelve-month basis in 2026, net income reached $24.2 million on revenue of $306.3 million.
MACI accounted for nearly 82% of Vericel's revenue in Q1 FY2026, so any weakness in biopsies or their conversion into implants could clearly affect overall results. The product also competes with Agili-C and microfracture augmentation products, despite management's assertion that the target patient categories differ and that Agili-C is not intended for patellar defects. In addition, the company is spending on expanding the sales team, the MACI ankle trial, and the Burlington facility, adding costs before these investments generate their full return.
Vericel's new facility received FDA approval for the commercial manufacturing of MACI, and manufacturing there began during Q2 FY2026. The facility increases the capacity needed for growth within the United States and enables potential commercialization outside it. The company was planning to submit a marketing application in the United Kingdom during FY2026, with a potential launch in 2027 subject to obtaining regulatory approval.
